

State of Oklahoma SoonerCare Gavreto™ (Pralsetinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Informa	ation
Pharmacy NPI:	Pharmacy Name:Pharmacy Fax:	
Pharmacy Phone:	Pharmacy Fax:_	
	Prescriber Information	on
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
B. Is NSCLC positive If diagnosis is not li Additional Information: For Continued Authorization 1. Date of last dose: 2. Does member have any of the second state o	ent, advanced, or metastatic? Yes ve for RET rearrangement? Yes isted above, please indicate diagon:	nosis: hile on pralsetinib? Yes Noed to pralsetinib therapy?
Prescriber Signature:		

rect to the best of my knowledge.

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

I certify that the indicated treatment is medically necessary and all information is true and cor-

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.